IL258139A - Nicotine compositions and methods for their preparation and use - Google Patents

Nicotine compositions and methods for their preparation and use

Info

Publication number
IL258139A
IL258139A IL258139A IL25813918A IL258139A IL 258139 A IL258139 A IL 258139A IL 258139 A IL258139 A IL 258139A IL 25813918 A IL25813918 A IL 25813918A IL 258139 A IL258139 A IL 258139A
Authority
IL
Israel
Prior art keywords
making
methods
same
nicotine formulations
nicotine
Prior art date
Application number
IL258139A
Other languages
English (en)
Hebrew (he)
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of IL258139A publication Critical patent/IL258139A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/20—Devices without heating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
IL258139A 2015-09-16 2018-03-15 Nicotine compositions and methods for their preparation and use IL258139A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/856,129 US11224594B2 (en) 2015-09-16 2015-09-16 Nicotine formulations and methods of making and using the same
PCT/US2016/051961 WO2017048972A1 (en) 2015-09-16 2016-09-15 Nicotine formulations and methods of making and using the same

Publications (1)

Publication Number Publication Date
IL258139A true IL258139A (en) 2018-05-31

Family

ID=58257033

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258139A IL258139A (en) 2015-09-16 2018-03-15 Nicotine compositions and methods for their preparation and use

Country Status (10)

Country Link
US (1) US11224594B2 (enExample)
EP (1) EP3349755B1 (enExample)
JP (1) JP2018527386A (enExample)
KR (1) KR102696600B1 (enExample)
CN (1) CN106539793B (enExample)
CA (1) CA2998950A1 (enExample)
IL (1) IL258139A (enExample)
MX (1) MX2018003271A (enExample)
RU (1) RU2722446C2 (enExample)
WO (1) WO2017048972A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
MX385972B (es) * 2016-06-30 2025-03-18 Philip Morris Products Sa Partículas y composiciones de nicotina.
WO2019003118A1 (en) * 2017-06-28 2019-01-03 Philip Morris Products S.A. CONTAINER WITH PARTICLES FOR USE WITH INHALER
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
CN113208148B (zh) * 2021-05-12 2022-11-04 云南中烟工业有限责任公司 一种协同释放尼古丁和致香成分的超分子凝胶
US12295412B2 (en) 2022-01-28 2025-05-13 Altria Client Services Llc Oral pouch product
CN120500327A (zh) * 2022-10-27 2025-08-15 韩国烟草人参公社 用于吸入的低剂量尼古丁干粉组合物
CN120417888A (zh) * 2022-10-27 2025-08-01 韩国烟草人参公社 用于吸入的尼古丁干粉的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441060A (en) 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
CA2146954C (en) 1995-04-12 2008-06-17 Arthur Slutsky Breath activated nicotine inhalers
CA2265198C (en) 1998-03-11 2009-01-27 Zamel, Noe Method of producing a nicotine medicament and a medicament made by the method
US20120042886A1 (en) 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6234169B1 (en) 1998-08-14 2001-05-22 Arthur Slutsky Inhaler
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
WO2001049274A2 (en) 1999-12-30 2001-07-12 Chiron Corporation Methods for pulmonary delivery of interleukin-2
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
US20060178394A1 (en) 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2005000267A2 (en) 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
CA2648291A1 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
EP2086317A4 (en) 2006-12-01 2010-03-03 Aradigm Corp NICOTINE FORMULATIONS, KITS AND SYSTEMS AND METHOD FOR THEIR USE
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
GB0709811D0 (en) 2007-05-22 2007-07-04 Vectura Group Plc Pharmaceutical compositions
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
KR20100069333A (ko) 2008-12-16 2010-06-24 홍성엽 흡입식 경구 투여 금연 보조제
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
GB201215273D0 (en) 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
PL2925395T3 (pl) 2012-11-28 2019-08-30 Fontem Holdings 1 B.V. Urządzenie wytwarzające aerozol kondensacyjny z ciekłej formulacji
US20140166027A1 (en) 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
US10357054B2 (en) 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
RU2016136348A (ru) * 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
KR20190075168A (ko) 2014-04-08 2019-06-28 필립모리스 프로덕츠 에스.에이. 니코틴 제형 및 이의 제조방법
CA2943459C (en) 2014-04-28 2023-05-02 Philip Morris Products S.A. Nicotine powder inhaler
CN106170313B (zh) 2014-04-28 2020-11-10 菲利普莫里斯生产公司 带香味尼古丁粉末吸入器
EP4603486A3 (en) * 2014-05-27 2025-10-15 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US9968125B2 (en) 2015-01-09 2018-05-15 Philip Morris Products S.A. Nicotine—diketopiperazine microparticle formulations and methods of making the same
US9585835B1 (en) 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same

Also Published As

Publication number Publication date
RU2018113272A3 (enExample) 2019-10-16
EP3349755A4 (en) 2019-04-24
CN106539793B (zh) 2020-06-30
RU2018113272A (ru) 2019-10-16
US11224594B2 (en) 2022-01-18
US20170071929A1 (en) 2017-03-16
EP3349755C0 (en) 2025-02-19
CA2998950A1 (en) 2017-03-23
EP3349755A1 (en) 2018-07-25
MX2018003271A (es) 2018-05-16
KR20180055819A (ko) 2018-05-25
KR102696600B1 (ko) 2024-08-21
JP2018527386A (ja) 2018-09-20
RU2722446C2 (ru) 2020-06-01
CN106539793A (zh) 2017-03-29
EP3349755B1 (en) 2025-02-19
WO2017048972A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
ZA201805805B (en) Formulations and methods
EP3129024A4 (en) Nicotine formulations and methods of making the same
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
IL256621A (en) Carrier-binder preparations and methods for their preparation and use
IL255801A (en) Liposomal nanoconstructs and methods of making and using the same
GB2525793B (en) Keratin treatment formulations and methods
IL258143A (en) Nicotine composition for inhalation and methods for their preparation and use
ZA202202259B (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
IL254398A0 (en) Antimicrobial compounds and methods for their preparation and use
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
GB201519128D0 (en) Solid forms and methods of preparing the same
IL265870A (en) Nanoparticle formulations and methods of making and using thereof
GB202201860D0 (en) Novel methods and compositions
EP3166892A4 (en) Scale-inhibition compositions and methods of making and using the same
EP3310354A4 (en) Improved formulations of deferasirox and methods of making the same
IL285928A (en) Fulvestrant formulations and methods of using them
IL266132A (en) Pharmacological formulations and methods for their preparation
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
PL3373910T3 (pl) Preparat echinomycyny, sposób wytwarzania i sposób stosowania
EP3448375C0 (en) BENZOYLGLYCINE DERIVATIVES AND METHODS OF PRODUCING AND USING SUCH DERIVATIVES
SG11201805812QA (en) Delayed-release formulations, methods of making and use thereof